Skip to main content

Advertisement

Fig. 2 | Clinical and Molecular Allergy

Fig. 2

From: Non-digestible oligosaccharides scFOS/lcFOS facilitate safe subcutaneous immunotherapy for peanut allergy

Fig. 2

Allergic manifestations evaluated in PE-sensitized mice after fed the scFOS/lcFOS supplemented diet and a singular SCIT dose. The effect of scFOS/lcFOS on the safety of SCIT in a peanut allergy model, according to treatment protocol 1 (Fig. 1). a Change in body temperature after SCIT challenge on day 42. b Anaphylactic shock symptom scores determined 40 min after SCIT challenge on day 42. c Concentrations of MMCP-1 in serum collected 30 min after SCIT challenge on day 42. d Cytokine concentrations (IL-5, IL-10, IL-13 and IFN-γ) after ex vivo stimulation of splenocytes with PE collected at day 43. eh Allergen-specific IgE, IgA, IgG1 and IgG2a measured by ELISA in serum of mice. Data are represented as mean ± SEM n = 6 mice/group, experiments were performed twice independently. Statistical analysis was performed using a two-way repeated measures ANOVA with Bonferroni’s post hoc test (body temperature), a one-way ANOVA with Bonferroni’s post hoc test (MMCP-1 and antibody levels), or a Kruskal–Wallis test with Dunn’s post hoc test (Clinical score and cytokine levels). For body temperature; ####P < 0.0001; ##P < 0.01 compared to the control group. **P < 0.01 compared to same group on control diet. For other results; ***P < 0.001; **P < 0.01; *P < 0.05 compared to indicated group. s.c., subcutaneous; i.g. intra gastric; PE, peanut extract; CNTR, control group; FF, scFOS/lcFOS; MMCP-1, mucosal mast cell protease-1; IL-, interleukin; IT, immunotherapy

Back to article page